AGBL2 and neoplasm: We suggest that RARRES1 and AGBL2 immunostaining may help to identify a group of patients at a low and high risk of tumour progression and may direct an active surveillance of patients with high risk to detect metastasis as early as possible and stop the follow-up for patients with excellent outcome.